BACKGROUND: The common Thr92Ala D2 polymorphism has been associated with changes in pituitary-thyroid axis homeostasis, but published results are conflicting. To investigate the effects of the Thr92Ala polymorphism on intrathyroidal thyroxine (T4) to triiodothyronine (T3) conversion, we designed prospective pharmacogenomic intervention aimed to detect differences in T3 levels after thyrotropin (TSH)-releasing hormone (TRH)-mediated TSH stimulation of the thyroid gland. METHODS: Eighty-three healthy volunteers were screened and genotyped for the Thr92Ala polymorphism. Fifteen volunteers of each genotype (Thr/Thr, Thr/Ala, and Ala/Ala) underwent a 500 mcg intravenous TRH stimulation test with serial measurements of serum total T3 (TT3), free T4, and TSH over 180 minutes. RESULTS: No differences in baseline thyroid hormone levels were seen among the study groups. Compared to the Thr/Thr group, the Ala/Ala group showed a significantly lower TRH-stimulated increase in serum TT3 at 60 minutes (12.07 ± 2.67 vs. 21.07 ± 2.86 ng/dL, p = 0.029). Thr/Ala subjects showed an intermediate response. Compared to Thr/Thr subjects, the Ala/Ala group showed a blunted rate of rise in serum TT3 as measured by mean time to 50% maximum delta serum TT3 (88.42 ± 6.84 vs. 69.56 ± 6.06 minutes, p = 0.028). Subjects attained similar maximal (180 minutes) TRH-stimulated TT3 levels. TRH-stimulated TSH and free T4 levels were not significantly different among the three genotype groups. CONCLUSIONS: The commonly occurring Thr92Ala D2 variant is associated with a decreased rate of acute TSH-stimulated T3 release from the thyroid consistent with a decrease in intrathyroidal deiodination. These data provide a proof of concept that the Thr92Ala polymorphism is associated with subtle changes in thyroid hormone homeostasis.
BACKGROUND: The common Thr92Ala D2 polymorphism has been associated with changes in pituitary-thyroid axis homeostasis, but published results are conflicting. To investigate the effects of the Thr92Ala polymorphism on intrathyroidal thyroxine (T4) to triiodothyronine (T3) conversion, we designed prospective pharmacogenomic intervention aimed to detect differences in T3 levels after thyrotropin (TSH)-releasing hormone (TRH)-mediated TSH stimulation of the thyroid gland. METHODS: Eighty-three healthy volunteers were screened and genotyped for the Thr92Ala polymorphism. Fifteen volunteers of each genotype (Thr/Thr, Thr/Ala, and Ala/Ala) underwent a 500 mcg intravenous TRH stimulation test with serial measurements of serum total T3 (TT3), free T4, and TSH over 180 minutes. RESULTS: No differences in baseline thyroid hormone levels were seen among the study groups. Compared to the Thr/Thr group, the Ala/Ala group showed a significantly lower TRH-stimulated increase in serum TT3 at 60 minutes (12.07 ± 2.67 vs. 21.07 ± 2.86 ng/dL, p = 0.029). Thr/Ala subjects showed an intermediate response. Compared to Thr/Thr subjects, the Ala/Ala group showed a blunted rate of rise in serum TT3 as measured by mean time to 50% maximum delta serum TT3 (88.42 ± 6.84 vs. 69.56 ± 6.06 minutes, p = 0.028). Subjects attained similar maximal (180 minutes) TRH-stimulated TT3 levels. TRH-stimulated TSH and free T4 levels were not significantly different among the three genotype groups. CONCLUSIONS: The commonly occurring Thr92Ala D2 variant is associated with a decreased rate of acute TSH-stimulated T3 release from the thyroid consistent with a decrease in intrathyroidal deiodination. These data provide a proof of concept that the Thr92Ala polymorphism is associated with subtle changes in thyroid hormone homeostasis.
Authors: Olga Gumieniak; Todd S Perlstein; Jonathan S Williams; Paul N Hopkins; Nancy J Brown; Benjamin A Raby; Gordon H Williams Journal: Hypertension Date: 2007-01-15 Impact factor: 10.190
Authors: Robin P Peeters; Annewieke W van den Beld; Hayat Attalki; Hans van Toor; Yolanda B de Rijke; George G J M Kuiper; Steven W J Lamberts; Joop A M J L Janssen; Andre G Uitterlinden; Theo J Visser Journal: Am J Physiol Endocrinol Metab Date: 2005-02-22 Impact factor: 4.310
Authors: Luis Henrique Canani; Clarissa Capp; José Miguel Dora; Erika L Souza Meyer; Márcia S Wagner; John W Harney; P Reed Larsen; Jorge L Gross; Antonio C Bianco; Ana Luiza Maia Journal: J Clin Endocrinol Metab Date: 2005-03-29 Impact factor: 5.958
Authors: Bente C Appelhof; Robin P Peeters; Wilmar M Wiersinga; Theo J Visser; Ellie M Wekking; Jochanan Huyser; Aart H Schene; Jan G P Tijssen; Witte J G Hoogendijk; Eric Fliers Journal: J Clin Endocrinol Metab Date: 2005-09-06 Impact factor: 5.958
Authors: Daniela Mentuccia; Matthew J Thomas; Giuseppe Coppotelli; Laurie J Reinhart; Braxton D Mitchell; Alan R Shuldiner; Francesco S Celi Journal: Thyroid Date: 2005-11 Impact factor: 6.568
Authors: Frank Jan de Jong; Robin P Peeters; Tom den Heijer; Wendy M van der Deure; Albert Hofman; André G Uitterlinden; Theo J Visser; Monique M B Breteler Journal: J Clin Endocrinol Metab Date: 2006-11-14 Impact factor: 5.958
Authors: Maya Y Peltsverger; Peter W Butler; Anna Teresa Alberobello; Sheila Smith; Yanina Guevara; Ornella M Dubaz; Javier A Luzon; Joyce Linderman; Francesco S Celi Journal: Eur J Endocrinol Date: 2012-02-03 Impact factor: 6.664
Authors: Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka Journal: Thyroid Date: 2014-12 Impact factor: 6.568
Authors: Antonio C Bianco; Alexandra Dumitrescu; Balázs Gereben; Miriam O Ribeiro; Tatiana L Fonseca; Gustavo W Fernandes; Barbara M L C Bocco Journal: Endocr Rev Date: 2019-08-01 Impact factor: 19.871
Authors: Sungro Jo; Tatiana L Fonseca; Barbara M L C Bocco; Gustavo W Fernandes; Elizabeth A McAninch; Anaysa P Bolin; Rodrigo R Da Conceição; Joao Pedro Werneck-de-Castro; Daniele L Ignacio; Péter Egri; Dorottya Németh; Csaba Fekete; Maria Martha Bernardi; Victoria D Leitch; Naila S Mannan; Katharine F Curry; Natalie C Butterfield; J H Duncan Bassett; Graham R Williams; Balázs Gereben; Miriam O Ribeiro; Antonio C Bianco Journal: J Clin Invest Date: 2018-12-03 Impact factor: 14.808